Randomized Study on Using Anthelios Fluide 100 KA UVMune 400 Sunscreen to Prevent Actinic Keratosis Damage in Adults Aged 60 and Older

What this Trial Is About

This research aims to study the protective effect of an investigational sunscreen called Anthelios Fluide 100 KA UVMune 400 on people diagnosed with multiple actinic keratosis lesions AK. AK lesions are small, rough, dry, scaly patches or bumps on the skin that can be skin-colored, pink, red, or tan and are often easier to feel than see in early stages. These lesions are common in adults, especially those aged 45 and older, and are considered pre-cancerous. Participants will be randomly assigned to one of two groups the intervention group will use the investigational sunscreen daily, applying it at least once every morning and reapplying during sun exposure, while following good sun protection habits such as seeking shade, wearing protective clothing, and hats. The control group will follow usual sun protection recommendations and may use their preferred broad-spectrum sunscreen with SPF 50 as usual. The study will observe participants over 9 months. During the study, researchers will assess the number of actinic keratosis lesions at the start and at 3, 6, and 9 months. Other evaluations include skin thickness, disease severity biomarkers, and participant self-assessments. Safety will be monitored by adverse event reports throughout the study. Participants will follow specific sun protection guidelines and apply the sunscreen as directed while researchers track changes in their skin condition and overall photoprotection.

Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses